Tandem Meetings 2023 | Latest advances in GvHD prophylaxis: TAC/MMF/PTCy & abatacept

Name: Latest advances in GvHD prophylaxis: TAC/MMF/PTCy & abatacept
Uploaded: 2023-02-16T00:00:00Z
Duration: 3 min 36 s

Rebecca Gonzalez • 16 Feb 2023

Tandem Meetings 2023

General Abatacept Cyclophosphamide Methotrexate Tacrolimus

BMT CTN 1703

Rebecca Gonzalez, PharmD, BCOP, Moffitt Cancer Center, Tampa, FL, gives an overview of the latest developments in strategies for graft-versus-host disease (GvHD) prevention, discussing the results of the BTM CTN 1703 (NCT03959241) study that showed the superiority of post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (TAC/MMF/PTCy) over tacrolimus/methotrexate (TAC/MTX), and discussing the efficacy and toxicity of abatacept. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.